Furmonertinib Mesylate
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Furmonertinib Mesylate, covering 2025-05-11 to 2025-05-11. Get the full timeline:
Most recent: Clinical Trial Update: To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer [Phase 2]